Review anchor
Vascular endothelial growth factor receptor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Vascular endothelial growth factor receptor 2
CHEMBL279
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Vascular endothelial growth factor receptor 2 as ChEMBL target CHEMBL279, mapped to UniProt P35968. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL279
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P35968
Vascular endothelial growth factor receptor 2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Vascular endothelial growth factor receptor 2 matters
Vascular endothelial growth factor receptor 2 is reviewed as Vascular endothelial growth factor receptor 2 (UniProt P35968); Vascular endothelial growth factor receptor 2 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 19 linked drugs keep this evidence frame grounded.; the current evidence base includes 65 approved drugs, 16926 compounds, and 2457 assays, with lead potency reaching pChEMBL 10.7.
Protein context
Vascular endothelial growth factor receptor 2
Vascular endothelial growth factor receptor 2 Sequence length is 1356 aa.
Review this target as Vascular endothelial growth factor receptor 2, mapped to UniProt P35968. Sequence length is 1356 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P35968
Protein
Disease context
neoplasm
Vascular endothelial growth factor receptor 2 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 19 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALTIRATINIB, BMS-817378, CABOZANTINIB S-MALATE.
Start review with neoplasm because it currently carries approved-linked support. Linked drugs include ALTIRATINIB, BMS-817378, CABOZANTINIB S-MALATE, CATEQUENTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
19 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 65 approved drugs, 16926 compounds, and 2457 assays for this target. The dominant activity type is IC50. CHEMBL3925855 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL3925855 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
65 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Vascular endothelial growth factor receptor 2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P35968, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
16926
Total Compounds
2457
Total Assays
65
Approved Drugs
IC50: 16863.0, KI: 1814.0, EC50: 27.0, KD: 295.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3925855
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL1289926
|
10.7 | IC50 | Approved |
|
|
No preferred name
CHEMBL1336
|
10.7 | Ki | Approved |
|
|
No preferred name
CHEMBL5189340
|
10.6 | IC50 | — |
|
|
No preferred name
CHEMBL1254007
|
10.6 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
QUIZARTINIB DIHYDROCHLORIDE
CHEMBL2105709
|
2023 |
|
|
QUIZARTINIB
CHEMBL576982
|
2023 |
|
|
FRUQUINTINIB
CHEMBL4303214
|
2023 |
|
|
INFIGRATINIB PHOSPHATE
CHEMBL1834657
|
2021 |
|
|
INFIGRATINIB
CHEMBL1852688
|
2021 |
|
|
SELPERCATINIB
CHEMBL4559134
|
2020 |
|
|
ENTRECTINIB
CHEMBL1983268
|
2019 |
|
|
PEXIDARTINIB
CHEMBL3813873
|
2019 |
|
|
ERDAFITINIB
CHEMBL3545376
|
2019 |
|
|
FOSTAMATINIB DISODIUM
CHEMBL3989516
|
2018 |
|
|
TIVOZANIB
CHEMBL1289494
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
LENVATINIB
CHEMBL1289601
|
2015 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
NINTEDANIB ESYLATE
CHEMBL3039504
|
2014 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
CABOZANTINIB
CHEMBL2105717
|
2012 |
|
|
CABOZANTINIB S-MALATE
CHEMBL2103868
|
2012 |
|
|
REGORAFENIB
CHEMBL1946170
|
2012 |
|
|
AXITINIB
CHEMBL1289926
|
2012 |
|
|
VANDETANIB
CHEMBL24828
|
2011 |
|
|
VEMURAFENIB
CHEMBL1229517
|
2011 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
SUNITINIB MALATE
CHEMBL1567
|
2006 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
SORAFENIB TOSYLATE
CHEMBL1200485
|
2005 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
GEFITINIB
CHEMBL939
|
2003 |
Source Header